{"analyses":[{"ciLowerLimit":"9.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"28.17","estimateComment":"The Estimate Value is a percentage.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"The Confidence Interval are percentages.","pValue":"<0.001","paramType":"Risk Difference (RD)","paramValue":"18.88","statisticalMethod":"Mantel Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).","groups":[{"description":"Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.","id":"OG000","title":"Asciminib (All Asciminib )"},{"description":"Patients took on ongoing basis the Investigator selected TKIs (imatinib, nilotinib, dasatinib or bosutinib)","id":"OG001","title":"Investigator Selected TKI (All Comparators)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Full Analysis Set (FAS) comprised of all participants to whom study treatment has been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"At 48 weeks","title":"Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI","type":"PRIMARY","unitOfMeasure":"Participants"}